5Ghosh S, Watts D, Kinnear M. Management of gas- trointestinal haemorrhage. Postgrad Med J 2002; 78: 4-14.
6Vreeburg EM, Levi M, Rauws EA, Deventer SJ, Snel P, Bartelsman JW, Ten Cate JW, Tytgat GN. En- hanced mucosal fibrinolytic activity in gastroduo- denal ulcer haemorrhage and the beneficial effect of acid suppression. Aliment Pharmacol Ther 2001; 15: 639-646.
7Simon B, Cremer M, Dammann HG, Hentschel E, Keohane PP, Mulder H, Mtlller P, Sarles H. 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe. Scand J Gastroenterol Suppl 1987; 136: 61-70.
8Breuer T, Kim JG, el-Zimaity HM, Nakajima S, Ota H, Osato M, Graham DY. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. Aliment Pharmacol Ther 1997; 11:939-942.
9Lo WC, Lin HJ, Wang K, Perng CL, Lee SD. Clar- ithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. Zhonghua Yixue Zazhi (Taipei) 1997; 59: 171-176.
10Thomson AB, Mahachai V, Bailey RJ, Kirdeikis P, Zuk L, Marriage B, Simpson I, Jamali F. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease. J Gastroenterol Hepatol 1996; 11:1171-1176.
